| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Strategy Officer | Chief Business Officer
1 company
Andrew Serafin is Chief Strategy Officer at HRMY. Andrew Serafin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $55K at current prices.
The HRMY filings lean toward selling, a net 38,000 shares.
Andrew Serafin has 6 Form 4 filings on record from August 2020 to January 2026, all as Chief Strategy Officer at Harmony Biosciences (HRMY), 2020–2026.
The 18 reported transactions were 7 option or other derivative awards, 4 option exercises, 3 tax withholdings and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $2.3M.
The only open-market sale was 38,000 shares of HRMY at an average $60.13 on December 2, 2022, about $2.3M. Twelve months later HRMY was down 50%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Chief Strategy Officer | Sale+OE | 38,000 | $60.13 | $2,285,099.92 | - | -29.0% | -49.6% |